FCA
IMDX

FinTrust Capital Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

FinTrust Capital Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed – – 1150
2019
Q4 		$0 Buy
+1
New +$36 ﹤0.01% 1100

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

FinTrust Capital Advisors's IMDX Position: Q1 2020 in Review

FinTrust Capital Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q1 2020, closing a stake of 1 share.

FinTrust Capital Advisors first reported a position in IMDX in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q1 2020.

  • FinTrust Capital Advisors reported no remaining Insight Molecular Diagnostics position as of Q1 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 1 Insight Molecular Diagnostics share in Q1 2020.
  • FinTrust Capital Advisors first reported a position in Insight Molecular Diagnostics in Q4 2019 and held it in 1 quarter.
  • FinTrust Capital Advisors's Insight Molecular Diagnostics position peaked at $0 in Q4 2019.
  • 56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2020.

Based on FinTrust Capital Advisors's 13F filing for Q1 2020, filed 15 May 2020.